Plato Investment Management Ltd Has $932,000 Stake in Insulet Co. (NASDAQ:PODD)

Plato Investment Management Ltd lowered its stake in shares of Insulet Co. (NASDAQ:PODD) by 23.8% during the second quarter, Holdings Channel.com reports. The institutional investor owned 4,619 shares of the medical instruments supplier’s stock after selling 1,441 shares during the quarter. Plato Investment Management Ltd’s holdings in Insulet were worth $932,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PODD. Sunbelt Securities Inc. acquired a new position in Insulet during the first quarter valued at approximately $29,000. International Assets Investment Management LLC acquired a new position in shares of Insulet in the 2nd quarter valued at $32,000. UMB Bank n.a. increased its position in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares in the last quarter. Jones Financial Companies Lllp bought a new stake in shares of Insulet in the 4th quarter valued at $40,000. Finally, CVA Family Office LLC raised its stake in Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on PODD shares. Canaccord Genuity Group reissued a “buy” rating and issued a $234.00 target price on shares of Insulet in a research note on Tuesday, July 23rd. UBS Group boosted their price objective on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Redburn Atlantic initiated coverage on shares of Insulet in a report on Thursday, May 30th. They set a “buy” rating and a $235.00 target price on the stock. Barclays upped their price target on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Finally, OTR Global restated a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.29.

Insulet Price Performance

Shares of NASDAQ PODD opened at $233.87 on Monday. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $234.71. The stock has a market capitalization of $16.38 billion, a price-to-earnings ratio of 70.87, a PEG ratio of 4.26 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The business has a 50-day moving average of $199.23 and a 200-day moving average of $186.02.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The company had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. During the same quarter in the prior year, the business earned $0.38 earnings per share. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, sell-side analysts predict that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.